186 related articles for article (PubMed ID: 32110296)
1. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies.
Hong H; Zhou Z; Zhou K; Liu S; Guo Z; Wu Z
Chem Sci; 2019 Oct; 10(40):9331-9338. PubMed ID: 32110296
[TBL] [Abstract][Full Text] [Related]
2. Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.
Hong H; Lin H; Li D; Gong L; Zhou K; Li Y; Yu H; Zhao K; Shi J; Zhou Z; Huang Z; Wu Z
Angew Chem Int Ed Engl; 2022 Sep; 61(38):e202208773. PubMed ID: 35891606
[TBL] [Abstract][Full Text] [Related]
3. Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life.
Liu J; Hong H; Shi J; Xie Y; Lu Z; Liu Z; Zhou Z; Bian Z; Huang Z; Wu Z
Eur J Pharm Sci; 2021 Oct; 165():105941. PubMed ID: 34256102
[TBL] [Abstract][Full Text] [Related]
4. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
5. Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy.
Hong H; Li C; Gong L; Wang J; Li D; Shi J; Zhou Z; Huang Z; Wu Z
Chem Sci; 2021 Feb; 12(12):4623-4630. PubMed ID: 34163726
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
7. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.
Gong L; Li Y; Cui K; Chen Y; Hong H; Li J; Li D; Yin Y; Wu Z; Huang Z
Small; 2021 Nov; 17(45):e2103463. PubMed ID: 34761524
[TBL] [Abstract][Full Text] [Related]
8. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
[TBL] [Abstract][Full Text] [Related]
9. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
10. Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity.
Dai S; Hong H; Zhou K; Zhao K; Xie Y; Li C; Shi J; Zhou Z; Nie L; Wu Z
J Med Chem; 2021 Apr; 64(8):4947-4959. PubMed ID: 33825469
[TBL] [Abstract][Full Text] [Related]
11. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
12. Antibody-dependent cellular phagocytosis of tropomyosin receptor kinase C (TrkC) expressing cancer cells for targeted immunotherapy.
Lai PS; Usama SM; Kiew LV; Lee HB; Chung LY; Burgess K; Kue CS
Cancer Immunol Immunother; 2022 Sep; 71(9):2099-2108. PubMed ID: 35032175
[TBL] [Abstract][Full Text] [Related]
13. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
14. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
15. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
[TBL] [Abstract][Full Text] [Related]
16. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
Front Immunol; 2021; 12():715719. PubMed ID: 34413859
[TBL] [Abstract][Full Text] [Related]
17. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
18. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.
Karpovsky B; Titus JA; Stephany DA; Segal DM
J Exp Med; 1984 Dec; 160(6):1686-701. PubMed ID: 6239899
[TBL] [Abstract][Full Text] [Related]
19. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
